All In Biotech

Drug Trial Radar · NCT05162118

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of VG161 in Combination With Nivolumab in Patients With Advanced Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Mar 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

51

Planned (sponsor's estimate)

Start

Mar 8, 2022

Primary completion

Mar 22, 2025

Study completion Dec 22, 2025

Sponsor

Lead sponsor
Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).

Conditions

  • Advanced Pancreatic Cancer

Interventions

  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with NivolumabDrug

    Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: 1 month
  2. Occurrence and numbers of DLT (phase 1)Time frame: 1 month
  3. Occurence and frequence of AE and SAE (phase 1)Time frame: 24 month
  4. DCR (phase 2)Time frame: 24 month
  5. RP2D (phase 1)Time frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.